Literature DB >> 22147286

Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants.

Omer Erdeve1, Sadik Yurttutan, Nahide Altug, Ramazan Ozdemir, Tulin Gokmen, Ugur Dilmen, Serife Suna Oguz, Nurdan Uras.   

Abstract

OBJECTIVE: To compare the efficacy and safety of oral versus intravenous ibuprofen for the pharmacological closure of patent ductus arteriosus (PDA) in less mature preterm infants.
DESIGN: Prospective, randomised controlled study.
SETTING: Tertiary neonatal intensive care unit. PATIENTS AND
INTERVENTIONS: The study enrolled 80 preterm infants with gestational age ≤28 weeks, birth weight <1000 g, postnatal age 48 to 96 h, and had echocardiographically confirmed significant PDA. Seventy extremely low birthweight (ELBW) preterm infants received either intravenous or oral ibuprofen randomly as an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h. MAIN OUTCOME MEASURES: The success rate and the safety of the drugs in ELBW preterm infants were the major outcomes.
RESULTS: PDA closure rate was significantly higher with oral ibuprofen (83.3% vs 61.7%) after the first course of the treatment (p=0.04). Although the primary closure rate was marginally higher in the oral ibuprofen group, the need for a second course of ibuprofen during the whole hospitalisation was similar between groups: 11 of 36 in oral versus 15 of 34 in intravenous groups (p=0.24) because of a higher reopening rate in the oral group. In addition to no increase in side effects with oral ibuprofen use, the need for postnatal steroid use for chronic lung disease was significantly lower in oral ibuprofen group (p=0.001).
CONCLUSIONS: Oral ibuprofen is as effective as intravenous ibuprofen for PDA closure even in ELBW infants.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22147286     DOI: 10.1136/archdischild-2011-300532

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  19 in total

1.  Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus.

Authors:  Gozde Kanmaz; Omer Erdeve; Fuat Emre Canpolat; Serife Suna Oğuz; Nurdan Uras; Nahide Altug; Ben Greijdanus; Uğur Dilmen
Journal:  Eur J Clin Pharmacol       Date:  2012-11-06       Impact factor: 2.953

Review 2.  Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus.

Authors:  Mehmet Yekta Oncel; Omer Erdeve
Journal:  World J Clin Pediatr       Date:  2016-02-08

3.  Efficacy and Costs of Three Pharmacotherapies for Patent Ductus Arteriosus Closure in Premature Infants.

Authors:  Ramesh Vidavalur
Journal:  Paediatr Drugs       Date:  2022-03-01       Impact factor: 3.022

Review 4.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

Review 5.  Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.

Authors:  Souvik Mitra; Ivan D Florez; Maria E Tamayo; Lawrence Mbuagbaw; Thuva Vanniyasingam; Areti Angeliki Veroniki; Adriana M Zea; Yuan Zhang; Behnam Sadeghirad; Lehana Thabane
Journal:  JAMA       Date:  2018-03-27       Impact factor: 56.272

6.  Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.

Authors:  Arne Ohlsson; Rajneesh Walia; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2020-02-11

7.  Eligibility Criteria and Representativeness of Randomized Clinical Trials That Include Infants Born Extremely Premature: A Systematic Review.

Authors:  Leeann R Pavlek; Brian K Rivera; Charles V Smith; Joanie Randle; Cory Hanlon; Kristi Small; Edward F Bell; Matthew A Rysavy; Sara Conroy; Carl H Backes
Journal:  J Pediatr       Date:  2021-04-21       Impact factor: 6.314

Review 8.  Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.

Authors:  Arne Ohlsson; Rajneesh Walia; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2018-09-28

Review 9.  Patent ductus arteriosus in preterm infants: do we have the right answers?

Authors:  Hesham Abdel-Hady; Nehad Nasef; Abd Elazeez Shabaan; Islam Nour
Journal:  Biomed Res Int       Date:  2013-12-23       Impact factor: 3.411

10.  Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial.

Authors:  Dan Dang; Dongxuan Wang; Chuan Zhang; Wenli Zhou; Qi Zhou; Hui Wu
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.